Meda denies acquisition talks with Sun Pharma

Meda informs the market that there are no discussions concerning merger with another pharmaceutical company.

Swedish drug firm AB, which has been reported to be in discussions with Industries for a $5 billion stake sale, today denied that it was in talks with any potential buyer.

"Due to the recent speculation in the press and media concerning merging with another pharmaceutical company, we have decided to inform the market that there are currently no such discussions," said in a statement.

Last week reports had said Mumbai-based Sun Pharma was in talks to buy the Swedish firm, which is strong in speciality products, over the counter drugs and branded generics, for about $5 billion.

"Meda's policy is not to comment on speculation and will not do so in the future. This announcement is an exception to our policy," it added.

While a spokesperson of Sun Pharma had earlier refused to comment on the reports, the Mumbai-based firm had also announced on that reports of a possible deal were "speculation".

"We have absolutely no comment on market speculation. Please further note since we have large cash and cash equivalents, we are constantly linked to rumours of international acquisitions," the company had said in a filing to the BSE.

Shares of Sun Pharma were trading 2.08% higher at Rs 1,040 apiece on the BSE.

image
Business Standard
177 22
Business Standard

Meda denies acquisition talks with Sun Pharma

Meda informs the market that there are no discussions concerning merger with another pharmaceutical company.

Press Trust of India  |  New Delhi 

Swedish drug firm AB, which has been reported to be in discussions with Industries for a $5 billion stake sale, today denied that it was in talks with any potential buyer.

"Due to the recent speculation in the press and media concerning merging with another pharmaceutical company, we have decided to inform the market that there are currently no such discussions," said in a statement.



Last week reports had said Mumbai-based Sun Pharma was in talks to buy the Swedish firm, which is strong in speciality products, over the counter drugs and branded generics, for about $5 billion.

"Meda's policy is not to comment on speculation and will not do so in the future. This announcement is an exception to our policy," it added.

While a spokesperson of Sun Pharma had earlier refused to comment on the reports, the Mumbai-based firm had also announced on that reports of a possible deal were "speculation".

"We have absolutely no comment on market speculation. Please further note since we have large cash and cash equivalents, we are constantly linked to rumours of international acquisitions," the company had said in a filing to the BSE.

Shares of Sun Pharma were trading 2.08% higher at Rs 1,040 apiece on the BSE.

RECOMMENDED FOR YOU

Meda denies acquisition talks with Sun Pharma

Meda informs the market that there are no discussions concerning merger with another pharmaceutical company.

Swedish drug firm Meda AB, which has been reported to be in discussions with Sun Pharmaceutical Industries for a $5 billion stake sale, today denied that it was in talks with any potential buyer.

Swedish drug firm AB, which has been reported to be in discussions with Industries for a $5 billion stake sale, today denied that it was in talks with any potential buyer.

"Due to the recent speculation in the press and media concerning merging with another pharmaceutical company, we have decided to inform the market that there are currently no such discussions," said in a statement.

Last week reports had said Mumbai-based Sun Pharma was in talks to buy the Swedish firm, which is strong in speciality products, over the counter drugs and branded generics, for about $5 billion.

"Meda's policy is not to comment on speculation and will not do so in the future. This announcement is an exception to our policy," it added.

While a spokesperson of Sun Pharma had earlier refused to comment on the reports, the Mumbai-based firm had also announced on that reports of a possible deal were "speculation".

"We have absolutely no comment on market speculation. Please further note since we have large cash and cash equivalents, we are constantly linked to rumours of international acquisitions," the company had said in a filing to the BSE.

Shares of Sun Pharma were trading 2.08% higher at Rs 1,040 apiece on the BSE.

image
Business Standard
177 22

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard